Journal of Neuro-Oncology

, Volume 68, Issue 3, pp 275–283 | Cite as

Correlation of Clinical Features and Methylation Status of MGMT Gene Promoter in Glioblastomas

  • J.L. Blanc
  • M. Wager
  • J. Guilhot
  • S. Kusy
  • B. Bataille
  • T. Chantereau
  • F. Lapierre
  • C.J. Larsen
  • L. Karayan-Tapon
Clinical Study

Abstract

In an effort to extend the potential relationship between the methylation status of MGMT promoter and response to CENU therapy, we examined the methylation status of MGMT promoter in 44 patients with glioblastomas. Tumor specimens were obtained during surgery before adjuvant treatment, frozen and stored at −80 °C until for DNA extraction process. DNA methylation patterns in the CpG island of the MGMT gene were determined in every tumor by methylation specific PCR (MSP). These results were then related to overall survival and response to alkylating agents using statistical analysis.

Methylation of the MGMT promoter was detected in 68% of tumors, and 96.7% of methylated tumors exhibited also an unmethylated status. There was no relationship between the methylation status of the MGMT promoter and overall survival and response to alkylating agents. Our observations do not lead us to consider promoter methylation of MGMT gene as a prognostic factor of responsiveness to alkylating agents in glioblastomas.

alkylating agents CENU grade IV gliomas methylation MGMT 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011–1018, 2002PubMedCrossRefGoogle Scholar
  2. 2.
    Ali-Osman F, Rairkar A, Young P: Formation and repair of 1,3-bis-(2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells. Cancer Biochem Biophys 14: 231–241, 1995PubMedGoogle Scholar
  3. 3.
    Ali-Osman F, Srivenugopal K, Berger MS, et al.: DNA interstrand crosslinking and strand break repair in human glioma cell lines of varying [1,3-bis(2-chloroethyl)-1-nitrosourea] resistance. Anticancer Res 10: 677–682, 1990PubMedGoogle Scholar
  4. 4.
    Bodell WJ, Gerosa M, Aida T, et al.: Investigation of resistance to DNA cross-linking agents in 9L cell lines with different sensitivities to chloroethylnitrosoureas. Cancer Res 45: 3460–3464, 1985PubMedGoogle Scholar
  5. 5.
    Silber JR, Bobola MS, Ghatan S, et al.: O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 58: 1068–1073, 1998PubMedGoogle Scholar
  6. 6.
    Silber JR, Mueller BA, Ewers TG, et al.: Comparison of O6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain. Cancer Res 53: 3416–3420, 1993PubMedGoogle Scholar
  7. 7.
    Mineura K, Izumi I, Watanabe K, et al.: O6-alkylguanine-DNA alkyltransferase activity in human brain tumors. Tohoku J Exp Med 165: 223–228, 1991PubMedCrossRefGoogle Scholar
  8. 8.
    Bredel M, Zentner J: Brain-tumour drug resistance: the bare essentials. Lancet Oncol 3: 397–406, 2002PubMedCrossRefGoogle Scholar
  9. 9.
    Day RS 3rd, Ziolkowski CH, Scudiero DA, et al.: Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains. Nature 288: 724–727, 1980PubMedCrossRefGoogle Scholar
  10. 10.
    Fornace AJ Jr., Papathanasiou MA, Hollander MC, et al.: Expression of the O6-methylguanine-DNA methyltransferase gene MGMT in MER+ and MER− human tumor cells. Cancer Res 50: 7908–7911, 1990PubMedGoogle Scholar
  11. 11.
    Pieper RO, Futscher BW, Dong Q, et al.: Comparison of O-6-methylguanine-DNA methyltransferase (MGMT) mRNA levels in Mer+ and Mer− human tumor cell lines containing the MGMT gene by the polymerase chain reaction technique. Cancer Commun 2: 13–20, 1990PubMedGoogle Scholar
  12. 12.
    Esteller M, Hamilton SR, Burger PC, et al.: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59: 793–797, 1999PubMedGoogle Scholar
  13. 13.
    Qian XC, Brent TP: Methylation hot spots in the 5′ flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res 57: 3672–3677, 1997PubMedGoogle Scholar
  14. 14.
    Watts GS, Pieper RO, Costello JF, et al.: Methylation of discrete regions of the O6-methylguanine-DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17: 5612–5619, 1997PubMedGoogle Scholar
  15. 15.
    Esteller M, Garcia-Foncillas J, Andion E, et al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350–1354, 2000PubMedCrossRefGoogle Scholar
  16. 16.
    Kleihues P, Sobin LH: World Health Organization classification of tumors. Cancer 88: 2887, 2000PubMedCrossRefGoogle Scholar
  17. 17.
    Herman JG, Graff JR, Myohanen S, et al.: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821–9826, 1996PubMedCrossRefGoogle Scholar
  18. 18.
    Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1953CrossRefGoogle Scholar
  19. 19.
    Peto R, Peto J: Asymptotically efficient rank invariant procedures (with discussion). J R Stat Soc A 135: 185–207, 1972CrossRefGoogle Scholar
  20. 20.
    Nakamura M, Watanabe T, Yonekawa Y, et al.: Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22: 1715–1719, 2001PubMedCrossRefGoogle Scholar
  21. 21.
    Jaeckle KA, Eyre HJ, Townsend JJ, et al.: Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 16: 3310–3315, 1998PubMedGoogle Scholar
  22. 22.
    Bhakat KK, Mitra S: Regulation of the human O6-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300. J Biol Chem 275: 34197–34204, 2000PubMedCrossRefGoogle Scholar
  23. 23.
    Harris LC, Remack JS, Houghton PJ, et al.: Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res 56: 2029–2032, 1996PubMedGoogle Scholar
  24. 24.
    Nutt CL, Loktionova NA, Pegg AE, et al.: O6-methylguanine-DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes. Carcinogenesis 20: 2361–2365, 1999PubMedCrossRefGoogle Scholar
  25. 25.
    Ali-Osman F, Srivenugopal K, Sawaya R: The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 344: 687 (author reply 687–688), 2001PubMedGoogle Scholar
  26. 26.
    Bearzatto A, Szadkowski M, Macpherson P, et al.: Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents. Cancer Res 60: 3262–3270, 2000PubMedGoogle Scholar
  27. 27.
    Christmann M, Pick M, Lage H, et al.: Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer 92: 123–129, 2001PubMedCrossRefGoogle Scholar
  28. 28.
    Belanich M, Pastor M, Randall T, et al.: Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56: 783–788, 1996PubMedGoogle Scholar
  29. 29.
    Mineura K, Izumi I, Watanabe K, et al.: Influence of O6-methylguanine-DNA methyltransferase activity on chloroethylnitrosourea chemotherapy in brain tumors. Int J Cancer 55: 76–81, 1993PubMedGoogle Scholar
  30. 30.
    Nagane M, Asai A, Shibui S, et al.: Expression of O6-methylguanine-DNA methyltransferase and chloroethylnitrosourea resistance of human brain tumors. Jpn J Clin Oncol 22: 143–149, 1992PubMedGoogle Scholar
  31. 31.
    Silber JR, Blank A, Bobola MS, et al.: O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 5: 807–814, 1999PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • J.L. Blanc
    • 1
    • 2
  • M. Wager
    • 2
  • J. Guilhot
    • 3
  • S. Kusy
    • 4
  • B. Bataille
    • 2
  • T. Chantereau
    • 1
  • F. Lapierre
    • 2
  • C.J. Larsen
    • 1
  • L. Karayan-Tapon
    • 1
  1. 1.Laboratory of Molecular OncologyIBMIGPoitiersFrance
  2. 2.Department of Neurological SurgeryCHULa MilétrieFrance
  3. 3.Department of Haematologic Oncology and Cellular TherapieCHULa MilétrieFrance
  4. 4.Laboratory of Human GeneticIBMIGPoitiersFrance

Personalised recommendations